ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "anti-TNF therapy"

  • Abstract Number: 1550 • 2014 ACR/ARHP Annual Meeting

    Prevalence of Enthesitis and Dactylitis, Impact on Disease Severity and Evolution over 12 Months in Psa Patients Treated with Anti-TNF in a Real-World Setting

    Proton Rahman1, Denis Choquette2, William Bensen3, Majed Khraishi4, Saeed Shaikh5, Regan Arendse6, Isabelle Fortin7, Andrew Chow8, Maqbool Sheriff9, Eliofotisti Psaradellis10, John S. Sampalis10, Susan Otawa11, Francois Nantel12, Allen J Lehman11 and May Shawi12, 1Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, 3Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 4Nexus Clinical Research, St John's, NF, Canada, 5McMaster University, Hamilton, ON, Canada, 6University of Saskatchewan, Saskatoon, SK, Canada, 7Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, 8University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, 9Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 10JSS Medical Research, Montreal, QC, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada, 12Janssen Inc., Toronto, ON, Canada

    Background/Purpose Spondyloarthritis, including psoriatic arthritis (PsA), is characterized by inflammatory arthritis affecting axial and peripheral joints. It is commonly associated with extra-articular and peri-articular manifestations…
  • Abstract Number: 566 • 2014 ACR/ARHP Annual Meeting

    Structural Progression of the Spine Measured By X-Ray in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol over 96 Weeks, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

    Désirée M. van der Heijde1, Walter P. Maksymowych2, Robert B. M. Landewé3, Christian Stach4, Owen Davies5, Tommi Nurminen4 and Jürgen Braun6, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Medicine, University of Alberta, Edmonton, AB, Canada, 3Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 4UCB Pharma, Monheim, Germany, 5UCB Pharma, Slough, United Kingdom, 6Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany

    Background/Purpose The impact of certolizumab pegol (CZP) on clinical and Magnetic Resonance Imaging outcomes in patients (pts) with axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS)…
  • Abstract Number: 75 • 2014 ACR/ARHP Annual Meeting

    Robust Identification of Anti-TNF Non-Responders in RA from Blood

    Ty Thomson, Reynald Lescarbeau, David Drubin, David Fryburg, David de Graaf, Renée Deehan, Daphna Laifenfeld and Aaron Van Hooser, Selventa, Cambridge, MA

    Background/Purpose: The number of biologic therapies approved for use in treating rheumatoid arthritis (RA) has grown steadily over the past 15 years.  While many patients…
  • Abstract Number: 2760 • 2013 ACR/ARHP Annual Meeting

    Incidence and Severity Of Myocardial Infarction In Subjects Receiving Anti Tumour Necrosis Factor Drugs For Rheumatoid Arthritis: Results From Linking the British Society For Rheumatology Biologics Register For Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project

    Audrey SL Low1, Kimme L. Hyrich2, Mark Lunt3, Louise K. Mercer3, Christopher Gale4,5, Kath Watson6, British Society for Rheumatology Biologics Registers (BSRBR) Control Centre Consortium1, William G. Dixon7, Deborah P. Symmons3,8 and On behalf of the BSRBR9, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 4Division of Epidemiology, Centre for Epidemiology and Biostatistics, University of Leeds, Leeds, United Kingdom, 5Department of Cardiology,York Teaching Hospital NHS Foundation Trust, York, United Kingdom, 6Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 7The University of Manchester, Manchester, United Kingdom, 8Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 9British Society for Rheumatology, London, United Kingdom

    Background/Purpose: Subjects with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared to subjects without RA, with the increased risk potentially driven…
  • Abstract Number: 2036 • 2013 ACR/ARHP Annual Meeting

    Biologic Therapy For Relapsing Polychondritis: Old and New Efficacy Indices

    Mattia Baldini1, Patrizia Aiello1, Mirta Tiraboschi1, Maria Grazia Sabbadini2 and Elena Baldissera1, 1Internal Medicine and Clinical Immunology, Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milano, Italy, 2Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milano, Italy

    Background/Purpose: The inflammatory milieu in affected tissues from Relapsing Polychondritis (RP) is rich in TNF-α, IL-1-β and IL-6. Cytokine-targeted biologic therapies has therefore been proposed…
  • Abstract Number: 1470 • 2013 ACR/ARHP Annual Meeting

    Anti-Tumour Necrosis Factor Alpha Therapy Reduces Platelet Reactivity and Is Associated With Improved Insulin Sensitivity In Patients With Inflammatory Arthritis

    Paul A. MacMullan1,2, Anne M. Madigan1, Laura J. Durcan3, Karl Egan2, Paola M. Bagaglia1, Dermot Kenny4 and Geraldine M. McCarthy1, 1Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, 2Cardiovascular Biology Laboratory, RCSI, Dublin, Ireland, 3Rheumatology, Mater Misercordiae University Hospital, Dublin 7, Ireland, 4Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland

    Background/Purpose: Patients with inflammatory arthritis (IA) die prematurely from cardiovascular disease (CVD). The increased CVD risk is not fully explained by traditional risk factors, but…
  • Abstract Number: 447 • 2013 ACR/ARHP Annual Meeting

    High Levels Of Memory B CELLS ARE Associated With Response To A First ANTI-TNF Drug In Patients With Rheumatoid Arthritis

    Claire I. Daien1,2, Sarah Gailhac3, Thibault Mura4, Bernard Combe2, Michael Hahne1 and Jacques Morel5, 1IGMM, CNRS UMR5535, Montpellier, Montpellier, France, 2Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, 3Igmm UMR3555, CNRS, Montpellier, France, 4CIC, Hopital Gui De Chauliac, Montpellier, France, 5Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France

    Background/Purpose: Tumor necrosis factor (TNF) inhibitors (TNFi) are effective treatments for rheumatoid arthritis (RA). Some reports suggested that TNFi affect B cell homeostasis.  We studied…
  • Abstract Number: 2678 • 2013 ACR/ARHP Annual Meeting

    Medically Significant Infections Are Increased In Patients With Juvenile Idiopathic Arthritis Treated With Etanercept. Results From The British Society For Paediatric and Adolescent Rheumatology Etanercept Cohort Study

    Rebecca Davies1, Taunton R. Southwood2, Lianne Kearsley-Fleet1, Mark Lunt3, Kimme L. Hyrich4 and on Behalf Of The BSPAR Etanercept Cohort Study5, 1Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 2Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 4Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 5Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom

    Background/Purpose: The association between anti-TNF therapy and increased rate of infection are widely documented in adults with rheumatoid arthritis. Findings in children with juvenile idiopathic…
  • Abstract Number: 1903 • 2013 ACR/ARHP Annual Meeting

    PIK3CD Overexpression In The Synovial Membrane Of Rheumatoid Arthritis Patients Is Associated With Response To Anti-TNF Therapy

    Antonio Julià1, Gabriela Ávila1, Raquel Celis2, Raimon Sanmarti3, Julio Ramirez4, Sara Marsal1 and Juan D. Cañete3, 1Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 2Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, 3Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 4Rheumatology, Hospital Clinic, Barcelona, Spain

    Background/Purpose: The mechanisms by which Rheumatoid Arthritis (RA) patients do not respond to TNF blockade are still poorly characterized. The goal of this study is…
  • Abstract Number: 1438 • 2013 ACR/ARHP Annual Meeting

    Comparative Effectiveness Of Rituximab Vs. Subsequent Anti-Tumor Necrosis Factor In Patients With Rheumatoid Arthritis With Prior Exposure To TNFi

    Leslie R. Harrold1, George W. Reed2, Robert P. Magner1, Ashwini Shewade3, Ani John3, Jeffrey D. Greenberg4 and Joel M. Kremer5, 1University of Massachusetts Medical School, Worcester, MA, 2CORRONA, Inc., Southborough, MA, 3Genentech Inc., South San Francisco, CA, 4NYU Hospital for Joint Diseases, New York, NY, 5Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: In patients (pts) who have failed 1 or more TNF-α inhibitors (TNFi), there is little data to guide clinical decision making in terms of…
  • Abstract Number: 431 • 2013 ACR/ARHP Annual Meeting

    Prediction Of Week 52 Treatment Response Based On A Week 12 Assessment In Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Comparison Of A Patient-Reported Instrument Versus Physician-Based Disease Activity Assessment

    Jeffrey R. Curtis1, Willem Koetse2, Jeymi Tambiah3, Lucian Ionescu4 and Yusuf Yazici5, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2UCB Pharma, Raleigh, NC, 3UCB Pharma, Smyrna, GA, 4UCB Pharma, Brussels, Belgium, 5New York University Hospital for Joint Diseases, New York, NY

    Background/Purpose: Guidelines support early intervention in rheumatoid arthritis (RA).1,2 The aim was to prospectively test whether outcome assessment at 12 weeks (wks) using a patient-reported…
  • Abstract Number: 2690 • 2013 ACR/ARHP Annual Meeting

    Survival Of The Second Biologic After The First Tumor Necrosis Factor Alpha Inhibitor’s Failure In The Treatment Of Rheumatoid Arthritis: Prospective Observational Data From Biorx.Si Registry

    ŽIga Rotar1 and Matija Tomsic2, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia

    Background/Purpose: Current recommendations for management of RA propose a tumor necrosis factor alpha inhibitor (TNFi) for patients failing to achieve the treatment target with synthetic…
  • Abstract Number: 1886 • 2013 ACR/ARHP Annual Meeting

    Differential Methylation Related To Response To Etanercept In Patients With Rheumatoid Arthritis

    Amy Webster1, Darren Plant2, Mark Lunt3, Stephen Eyre4, Edward Flynn4, Paul Martin5, A. G. Wilson6, A. W. Morgan7, John Isaacs8, Jane Worthington1,9 and Anne Barton2,4, 1Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, 2NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 4Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 5Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 6Genomic Medicine, The University of Sheffield, Sheffield, United Kingdom, 7Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, 8National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom, 9The University of Manchester, Manchester, United Kingdom

    Background/Purpose: The introduction of biologic drug therapies targeting specific components of the inflammatory response represents a huge advance in the treatment of rheumatoid arthritis (RA).…
  • Abstract Number: 1436 • 2013 ACR/ARHP Annual Meeting

    Early Changes In a Multi-Biomarker Disease Activity Score After Starting Adalimumab Treatment Predict Change In MRI Inflammation At 6 Months

    Simon Krabbe1, R.J. Bolce2, Cecilie Heegaard Brahe3, Uffe Møller Døhn3, Scott Cruickshank4, Bo J. Ejbjerg5, Merete L. Hetland3, E.H. Sasso2, D. Chernoff6, Michael Sejer Hansen7, Lene Surland Knudsen8, Annette Hansen9, Ole Rintek Madsen9, Maria Hasselquist10, Jakob M. Møller11 and Mikkel Østergaard3, 1Department of Rheumatology, Copenhagen University Hospital Glostrup, Copenhagen, Denmark, 2Crescendo Bioscience Inc., South San Francisco, CA, 3Copenhagen University Hospital Glostrup, Copenhagen, Denmark, 4Scott Cruickshank and Associates, Inc., Santa Barbara, CA, 5Slagelse Sygehus, Slagelse, Denmark, 6Crescendo Bioscience, Inc., South San Francisco, CA, 7Gildhøj Privathospital, Copenhagen, Denmark, 8Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, 9Copenhagen University Hospital Gentofte, Copenhagen, Denmark, 10Copenhagen University Hospital Herlev, Copenhagen, Denmark, 11Department of Radiology, Copenhagen University Hospital Herlev, Copenhagen, Denmark

    Background/Purpose: A multi-biomarker disease activity (MBDA) score has been validated as a measure of disease activity in rheumatoid arthritis. This study aimed to see if…
  • Abstract Number: 342 • 2013 ACR/ARHP Annual Meeting

    TNF Blockage In Psoriatic Arthritis: Long-Term Effect On Lipid Profile

    Julio C. B. Moraes1, Carla G.S. Saad1, Ana Cristina Ribeiro2, Claudia G Schainberg3, Celio R. Gonçalves2, Percival D Sampaio-Barros1 and Eloisa Bonfá2, 1Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Psoriatic arthritis (PsA) patients have increased cardiovascular morbidity and mortality. Altered lipid profile is an important risk factor for the development of these complications.…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology